[HTML][HTML] Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American …
K Tarlock, ML Sulis, JH Chewning, JA Pollard… - … and Cellular Therapy, 2022 - Elsevier
The role of allogeneic hematopoietic stem cell transplantation (HCT) in the treatment of
acute myelogenous leukemia (AML) in children is reviewed and critically evaluated in this …
acute myelogenous leukemia (AML) in children is reviewed and critically evaluated in this …
Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia
J Marvin-Peek, BN Savani, OO Olalekan, B Dholaria - Cancers, 2022 - mdpi.com
Simple Summary Chimeric antigen receptor (CAR) therapy has increased treatment options
for many patients who have failed standard chemotherapy. So far, CAR therapy has been …
for many patients who have failed standard chemotherapy. So far, CAR therapy has been …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy
Y Fløisand, M Remberger, I Bigalke, D Josefsen… - Leukemia, 2023 - nature.com
Intensive induction chemotherapy achieves complete remissions (CR) in> 60% of patients
with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not …
with acute myeloid leukemia (AML) but overall survival (OS) is poor for relapsing patients not …
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
M Boyiadzis, MJ Zhang, K Chen, H Abdel-Azim… - Leukemia, 2023 - nature.com
We investigated the impact of the number of induction/consolidation cycles on outcomes of
3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo …
3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo …
Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
Purpose: We evaluated outcomes of unrelated transplantation for primary
refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according …
refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according …
[HTML][HTML] Recent advances in nanomaterials for modulation of stem cell differentiation and its therapeutic applications
Challenges in directed differentiation and survival limit the clinical use of stem cells despite
their promising therapeutic potential in regenerative medicine. Nanotechnology has …
their promising therapeutic potential in regenerative medicine. Nanotechnology has …
Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia
Y Shimomura, T Sobue, S Hirabayashi, T Kondo… - Leukemia, 2022 - nature.com
Cord blood transplantation (CBT) is an alternative donor transplantation method and has the
advantages of rapid availability and the possibility of inducing a more potent graft-versus …
advantages of rapid availability and the possibility of inducing a more potent graft-versus …
TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell …
Simple Summary TP53 mutations are adverse-risk genetic aberrations in acute myeloid
leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53 MUT) …
leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53 MUT) …
How I treat with maintenance therapy after allogeneic HCT
Z DeFilipp, YB Chen - Blood, 2023 - ashpublications.org
Disease relapse is the leading cause of failure for patients receiving allogeneic
hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo …
hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo …